During the past decade, Institute of Hematology and Transfusion Medicine conducted 12 clinical trials. In the 10-year time frame, 12 clinical trials started and 8 clinical trials were completed, i.e. on average, 66.7% percent of trials that started reached the finish line to date. In the past 5 years, 5 clinical trials started and 3 clinical trials were completed. i.e. 60% of trials that started reached the finish line.

Out of the total clinical trials conducted in "Institute of Hematology and Transfusion Medicine" #1 sponsor was "Baxalta now part of Shire" with 4 trials, followed by "AOP Orphan Pharmaceuticals AG" with 3 trials sponsored, "Incyte Corporation" with 3 trials sponsored, "Astellas Pharma Inc" with 2 trials sponsored and "Celgene" with 2 trials sponsored. Other sponsors include 5 different institutions and companies that sponsored additional 15 trials in total.

In terms of collaborators to trials, out of the total clinical trials conducted in "Institute of Hematology and Transfusion Medicine" #1 collaborator was "Laboratoire français de Fractionnement et de Biotechnologies" with 1 trials as a collaborator, "Medical Research Agency, Poland" with 1 trials as a collaborator, "Medpace, Inc." with 1 trials as a collaborator, "PharmaEssentia (Co-Sponsor for USA)" with 1 trials as a collaborator and "PharmaEssentia Corporation (Co-Sponsor for USA)" with 1 trials as a collaborator. Other collaborators include -3 different institutions and companies that were collaborators in the rest 7 trials.

According to Clinical.Site data, the most researched conditions in "Institute of Hematology and Transfusion Medicine" are "Polycythemia Vera" (3 trials), "Acute Myeloid Leukemia" (2 trials), "Hemophilia B" (2 trials), "Myelofibrosis" (2 trials) and "Post Essential Thrombocythemia Myelofibrosis" (2 trials). Many other conditions were trialed in "Institute of Hematology and Transfusion Medicine" in a lesser frequency.

Most popular intervention types in "Institute of Hematology and Transfusion Medicine" are "Drug" (20 trials), "Biological" (5 trials), "Other" (3 trials) and "Procedure" (1 trials). Other intervention types were less common.

The name of intervention was led by "Placebo" (3 trials), "placebo" (3 trials), "FK463" (2 trials), "parsaclisib" (2 trials) and "ruxolitinib" (2 trials). Other intervention names were less common.

The vast majority of trials in "Institute of Hematology and Transfusion Medicine" are 23 trials for "All" genders and 1 trials for "Male" genders.

Currently, there are NaN active trials in "Institute of Hematology and Transfusion Medicine". 1 are not yet recruiting, 2 are recruiting, 4 are Active, not recruiting, and undefined are Enrolling by invitation. In total, there were 14 completed trials in Institute of Hematology and Transfusion Medicine, undefined suspended trials, and 1 terminated clinical trials to date.

Out of the total trials that were conducted in Institute of Hematology and Transfusion Medicine, 3 "Phase 1" clinical trials were conducted, 7 "Phase 2" clinical trials and 16 "Phase 3" clinical trials were conducted as well. "Phase 4" trials included 0 trials, and there were also 0 trials that are defined as “Not Applicable".